Form 4: Edwards Lifesciences CFO Scott Ullem Reports Stock Transactions

CVP and CFO of Edwards Lifesciences, Scott B. Ullem, reports transactions involving common stock and performance rights.

Summary

• Scott B. Ullem, CVP and Chief Financial Officer of Edwards Lifesciences, filed a Form 4 detailing changes in beneficial ownership.
• On May 3, 2024, 634 shares of common stock were disposed of at a price of $85.06.
• On May 4, 2024, 7,465 shares of common stock were acquired at $0, and 4,431 shares were disposed of at $85.25.
• These transactions resulted in a direct ownership of 21,474 shares of common stock and indirect ownership of 266,318 shares held in trust.
• Additionally, 7,465 performance rights were exercised on May 4, 2024, converting into common stock.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions, which are neither particularly positive nor negative. The vesting of performance rights suggests that performance targets were met, which is a mildly positive signal.

Positives

• The vesting of performance rights indicates that performance targets were met, leading to the acquisition of 7,465 shares.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like Edwards Lifesciences.
• Similar filings are made by executives at comparable companies such as Medtronic, Abbott Laboratories, and Boston Scientific.
• The size and frequency of these transactions are typical for executives at this level.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive stock ownership.
• The vesting of performance rights may have a minor positive impact on employee morale.

Key Dates